Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the editor

Parsonage-Turner syndrome and SARS-CoV-2 infection: A case report

A R T I C L E   I N F O

Keywords:
Parsonage Turner syndrome
COVID-19
Viral infection
Upper extremity

Mots-clés:
Parsonage-Turner
Covid-19
Infection virale
Membre supérieur

Syndrome de Parsonage-Turner et infection au SRAS COVID-19 : à propos d’un cas

Dear Editor-in-Chief,

Parsonage-Turner syndrome (PTS), also known as idiopathic brachial plexopathy or brachial neuritis, is a rare condition (1.64 cases per 100,000 people) that affects young adults, although some cases have been reported in adults over 60 years of age [1]. It is mainly characterized by severe acute, unilateral shoulder pain that can extend to the rest of the arm [1]. The latter is not position dependent and subsides after 1–2 weeks. Weakness, muscle atrophy and paresthesia appear and then gradually recede [1,2]. While the diagnosis is mainly based on clinical findings, electromyography (EMG) and magnetic resonance imaging (MRI) examinations are essential to confirming the PTS diagnosis [3]. Treatment is based on class I (or higher) analgesics and corticosteroid therapy [4,5]. The etiology and pathophysiological are not well understood, although some precipitating situations have been identified, such as the post-operative, post-infection (viral in 25%-55% of cases) and post-vaccination period [1,3].

PTS has been reported recently following COVID-19 infections [2,6–9]. Here, we report one case of PTS involving the long thoracic and spinal accessory nerves. This was a 22-year-old male with no relevant history except for an episode of anterior dislocation of his right shoulder. Upon sudden development of torticollis, he took at PCR test for COVID-19 that came back positive. Three weeks later, he presented at the emergency room because of pain in his cervical spine and right upper limb, with no signs of trauma. No paresthesia was present.

During the clinical examination, the patient had limited shoulder motion in abduction (45°) due to pain with visible atrophy of the trapezius muscle relative to the other side. He was unable to push against resistance in forward flexion. When examining his scapulothoracic region, there was an obvious winged scapula that mainly affected its medial edge and the ropey tendon of the inferior (ascending) portion of the trapezius was absent [4,10].

Given this presentation, EMG testing and MRI were requested. The EM revealed denervation of the trapezius and serratus anterior muscles, while the MRI showed hyperintensity (edema) associated with denervation of these two muscles, confirming the diagnosis (Fig. 1). A 7-day course of oral corticosteroids was prescribed in combination with rehabilitation.

At the 6-month follow-up visit (Fig. 2), the shoulder’s range of motion had improved with forward flexion of 100° and strength graded as 4/5 on the British Medical Council scale. Pain had disappeared and was graded as 0/10 on a visual analog scale. Conversely, the winged scapula was still present upon clinical examination, but the trapezius muscle was no longer visibly atrophied. A second MRI at 5 months showed persistent residual atrophy of the serratus anterior, but no edema in the trapezius muscle (Fig. 3).

In this clinical case, and given the suggestive clinical profile, EMG and MRI findings, we concluded that the long thoracic and spinal accessory nerves were involved. To our knowledge, this is the first reported case in France of PTS developing following a COVID-19 infection with long thoracic nerve involvement [2,3,7–9]. Two French articles have already mentioned isolated spinal accessory nerve and phrenic nerve involvement in PTS post-COVID-19 [6,11].

Knowing the timeline of the symptoms was essential to making the diagnosis as it allowed us to identify the triggering factor. In this case, there was a clear correlation with COVID-19 infection. Although some post-vaccination cases have been reported [12–15], PTS in our patient was likely not associated with vaccination, as he had been vaccinated a few months prior. We also systematically ruled out differential diagnoses for PTS, such as adhesive capsulitis, cervical hernia, subacromial bursitis, or even calcific tendinopathy of the supraspinatus [1].

Use of oral corticosteroids during the first month combined with physiotherapy helped to accelerate recovery [1,2,4,5]. As a general rule, complete PTS recovery occurs in 36% of patients at 1 year, 75% at 2 years and 89% at 3 years [16]. In our case, the patient had not recovered a functional range of motion 6 months after.
after PTS. This is consistent with the results described by Diaz et al. [3]; however, different nerves were involved. While not serious in the majority of cases, one study found PTS with an isolated phrenic nerve lesion, leading to diaphragm paralysis and a stay in the intensive care unit [6]. Thus, this pathology must not be underestimated.

Fig. 1. Intra-muscular edema in the serratus anterior and trapezius muscles is evidence of denervation.

Fig. 2. Examination of the scapulothoracic region 6 months after the COVID-19 infection.

Fig. 3. MRI done at 5 months showing persistent atrophy of the serratus anterior muscle.

Author contributions
All authors attest that they meet the current International Committee of Medical Journal Editors (ICMJE) criteria for Authorship.

Conflict of interest
Laurent Obert has no specific conflict of interest related to this study but has relationships with the following organizations: FX SolutionsTM, MedartisTM, EvolutisTM, Keri MedicalTM, ElsevierTM, CHRU of Besançon, University of Bourgogne Franche-Comté.
The other authors have no conflicts of interest to declare.

Funding
None.

Informed consent
The authors declare that the patient’s informed consent was collected.

References
[1] Feinberg JH, Radecki J. Parsonage-Turner syndrome. HSS J 2010;6:199–205.
[2] Mitry MA, Collins LK, Kazam JJ, Kaicker S, Kovankikaya A. Parsonage-Turner syndrome associated with SARS-CoV2 (COVID-19) infection. Clin Imaging 2021;72:8–10.
[3] Díaz C, Contreras JJ, Muñoz M, Osorio M, Quiróz M, Pizarro R. Parsonage-Turner syndrome association with SARS-CoV-2 infection. JSES Rev Rep Tech 2021;1:252–6.

[4] Seror P. Neuropathic amyotrophy. An update. Joint Bone Spine 2017;84:153–8.

[5] van Eijk JJ, van Allen N, Berrevoets M, van der Wilt GJ, Pillen S, van Engelen BGM. Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study. J Neurol Neurosurg Psychiatry 2009;80:1120–4.

[6] Viatge T, Noël-Savina E, Prévot G, Favier G, Plat G, De Boisseson X, et al. Syndrome de Parsonage-Turner compliquant une infection sévère à SARS-CoV-2, Rev Mal Respir 2021;38:853–8.

[7] Cabrera Pivral CE, Rincón Sánchez AR, Dávalos Rodríguez NO, Ramirez García SA. Parsonage-Turner syndrome associated with COVID-19: About two family cases. Neurologia 3 févr 2022 [Ahead of print].

[8] Voss TG, Stewart CM. Case report: Parsonage-Turner syndrome after COVID-19 infection. JSES Rev Rep Tech 2022;2:182–5.

[9] Alvarado M, Lin-Miao Y, Carrillo-Arolas M. Síndrome de Parsonage-Turner postinfección por SARS-CoV-2: a propósito de un caso. Neurología 2021;36:568–71.

[10] Seror P, Lenglet T, Nguyen C, Ouaknine M, Lefèvre-Colau MM. Unilateral winged scapula: clinical and electrodiagnostic experience with 128 cases, with special attention to long thoracic nerve palsy. Muscle Nerve 2018;57:913–20.

[11] Coll C, Tessier M, Vandendries C, Seror P. Névralgie amyotrophante et infection à COVID-19 : deux cas de paralysie du nerf spinal accessoire. Rev Rhum Ed Fr 2022;89:92–5.

[12] Coffman JR, Randolph AC, Somerson JS. Parsonage-Turner syndrome after SARS-CoV-2 BNT162b2 vaccine: a case report. JBJS Case Connect 2021;11.

[13] Vitturi BK, Grandis M, Beltramini S, Orsi A, Schenone A, Icardi G, et al. Parsonage–Turner syndrome following coronavirus disease 2019 immunization with ChAdOx1-S vaccine: a case report and review of the literature. J Med Case Rep 2021;15(1):589.

[14] Flikkema K, Brosy K. Parsonage-Turner syndrome after COVID-19 vaccination: a case report. JBJS Case Connect 2021;11.

[15] Mahajan S, Zhang F, Mahajan A, Zimnowodzki S. Parsonage-Turner syndrome after COVID-19 vaccination. Muscle Nerve 2021;64(1):E3–4. http://dx.doi.org/10.1002/mus.27255. Epub 2021 May 4. PMID: 33890680; PMCID: PMC8250573.

[16] Tsarís P, Dyck PJ, Mulder DW. Natural history of brachial plexus neuropathy: report on 99 patients. Arch Neurol 1972;27:109–17.

F. Saade, C. Bouteille, A. Quemener-Tanguy et al.

*Brotbeck, Traumatology, Plastic & Reconstructive Surgery Unit, Hand Surgery Unit, University, Hospital J. Minjoz, Besançon, France
*NanoMedicine Research Unit University of Franche-Comté, 19 Rue Ambroise Paré, 25030 Besançon Cedex, France
*Corresponding author

E-mail address: francoissaade@wanadoo.fr (F. Saade)

Received 28 June 2022
Available online 20 October 2022